Amgen and Kyowa Kirin see breakthrough in rocatinlimab Phase 3 Trial, eyes on FDA path
Amgen and Kyowa Kirin have reported positive top-line results from the Rocatinlimab Phase 3 IGNITE trial, part of the broader ROCKET Phase 3 program, which ... Read More
Amgen and AstraZeneca’s Tezspire achieves key milestone in Phase 3 nasal polyps trial
Amgen and AstraZeneca have revealed promising results from the Phase 3 Waypoint trial, demonstrating that Tezspire (tezepelumab-ekko) delivers significant and sustained relief for patients suffering ... Read More
Amgen reports strong Q4 growth amid expanding product sales and biotech innovations
Amgen’s revenue growth for the fourth quarter of 2024 exceeded analyst expectations, reflecting the company’s expanding biopharmaceutical portfolio and solid market positioning. The biotechnology giant ... Read More
Amgen’s Blincyto gains EU approval for consolidation phase treatment in B-ALL
Amgen has received European Commission approval for Blincyto (blinatumomab) as part of consolidation therapy in adults with newly diagnosed Philadelphia chromosome-negative CD19-positive B-cell precursor acute ... Read More
FDA approves Amgen’s BLINCYTO for expanded use in B-ALL treatment
Amgen (NASDAQ: AMGN) has achieved a significant milestone with the recent U.S. Food and Drug Administration (FDA) approval of BLINCYTO (blinatumomab) for the consolidation phase ... Read More
COURSE trial reveals promising results for TEZSPIRE in COPD patients with high eosinophil counts
In a significant development in chronic obstructive pulmonary disease (COPD) management, the Phase IIa COURSE trial, a proof-of-concept study led by AstraZeneca in partnership with ... Read More
Amgen seeks European approval for teprotumumab in thyroid eye disease
Amgen (NASDAQ: AMGN), a global biotechnology leader, has announced its plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ... Read More
Quantinuum closes $300m equity fundraise, valued at $5bn pre-money
Quantinuum, a global leader in integrated quantum computing, has announced the closing of a substantial $300 million equity fundraise. This financial milestone, achieved at a ... Read More
Glenmark Pharmaceuticals secures FDA approval for generic version of Otezla Tablets
Glenmark Pharmaceuticals Ltd. has successfully secured the final approval from the United States Food & Drug Administration (U.S. FDA) for its Apremilast Tablets in 10 ... Read More
Amgen to acquire Irish biopharma company Horizon Therapeutics for $28bn
Amgen through its wholly-owned subsidiary Pillartree has agreed to acquire Ireland-based biopharmaceutical firm Horizon Therapeutics for an enterprise value of around $28.3bn. The US biotechnology ... Read More